Insider Selling: Artivion, Inc. (NYSE:AORT) CFO Sells 3,259 Shares of Stock

Artivion, Inc. (NYSE:AORT - Get Free Report) CFO Lance A. Berry sold 3,259 shares of the business's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $27.31, for a total value of $89,003.29. Following the transaction, the chief financial officer now owns 75,805 shares in the company, valued at $2,070,234.55. This represents a 4.12 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Artivion Price Performance

Artivion stock traded down $0.02 during trading hours on Friday, hitting $25.34. 568,539 shares of the stock were exchanged, compared to its average volume of 404,014. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88. The stock has a market capitalization of $1.06 billion, a P/E ratio of -1,267.00 and a beta of 1.75. Artivion, Inc. has a 12 month low of $18.38 and a 12 month high of $32.33. The business's 50-day moving average is $29.51 and its two-hundred day moving average is $27.82.

Artivion (NYSE:AORT - Get Free Report) last announced its earnings results on Monday, February 24th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of $0.12 by ($0.51). The business had revenue of $97.31 million for the quarter, compared to the consensus estimate of $100.82 million. Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. Equities research analysts expect that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Remove Ads

Hedge Funds Weigh In On Artivion

Hedge funds have recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC boosted its holdings in Artivion by 236.7% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company's stock valued at $32,000 after acquiring an additional 786 shares during the last quarter. Quarry LP grew its holdings in Artivion by 210.8% during the 3rd quarter. Quarry LP now owns 1,209 shares of the company's stock worth $32,000 after acquiring an additional 820 shares during the period. R Squared Ltd acquired a new stake in Artivion during the 4th quarter worth $39,000. Arcadia Investment Management Corp MI acquired a new stake in Artivion during the 4th quarter worth $43,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Artivion during the 4th quarter worth $64,000. Institutional investors own 86.37% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on AORT shares. Needham & Company LLC lowered their price target on Artivion from $34.00 to $32.00 and set a "buy" rating on the stock in a research note on Tuesday, February 25th. Stifel Nicolaus lowered their price target on shares of Artivion from $33.00 to $30.00 and set a "buy" rating on the stock in a report on Tuesday, February 25th. Oppenheimer boosted their price target on shares of Artivion from $30.00 to $32.00 and gave the company an "outperform" rating in a report on Friday, November 8th. Finally, JMP Securities reissued a "market outperform" rating and issued a $33.00 price target on shares of Artivion in a report on Tuesday, December 10th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Artivion has a consensus rating of "Buy" and an average price target of $31.40.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.